Evidence map›Paper›PMID 24809301›Full record

ArticleAnnals of surgical oncology2014

Cost of contralateral prophylactic mastectomy.

Ashish A Deshmukh, Scott B Cantor, Melissa A Crosby, Wenli Dong, Yu Shen, Isabelle Bedrosian, Susan K Peterson, Patricia A Parker, Abenaa M Brewster

Abstract read
In one paragraph

Article in Annals of surgical oncology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Cost and Complications of Local Therapies for Early-Stage Breast Cancer.Journal of the National Cancer Institute · 2017
    Article
  12. Review
  13. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Ashish A DeshmukhDepartment of Health Services Research - Unit 1444, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Scott B Cantor
Melissa A Crosby
Wenli Dong
Yu Shen
Isabelle Bedrosian
Susan K Peterson
Patricia A Parker
Abenaa M Brewster

Funding

Tumor Evolution and Metastasis ProgramP30CA016672 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI Scott Kopetz · 1985 to 2026
$290.8M
A Decision Making Framework for Contralateral Prophylactic MastectomyR21CA149803 · NCI · UNIVERSITY OF TX MD ANDERSON CAN CTR · PI BREWSTER, ABENAA M, PARKER, PATRICIA A · 2010 to 2011
$372k
NCI NIH HHS 5 R21 CA149803NCI NIH HHS P30 CA016672NCI NIH HHS P30CA016672NCI NIH HHS R21 CA149803
6 · The paper itself

Abstract

purposeTo compare the healthcare costs of women with unilateral breast cancer who underwent contralateral prophylactic mastectomy (CPM) with those of women who did not.

methodsWe conducted a retrospective study of 904 women treated for stage I-III breast cancer with or without CPM. Women were matched according to age, year at diagnosis, stage, and receipt of chemotherapy. We included healthcare costs starting from the date of surgery to 24 months. We identified whether care was immediate or delayed (CPM within 6 months or 6-24 months after initial surgery, respectively). Costs were converted to approximate Medicare reimbursement values and adjusted for inflation. Multivariable regression analysis was performed to evaluate the effect of CPM on total breast cancer care costs adjusting for patient characteristics and accounting for matched pairs.

resultsThe mean difference between the CPM and no-CPM matched groups was $3,573 (standard error [SE] $455) for professional costs, $4,176 (SE $1,724) for technical costs, and $7,749 (SE $2,069) for total costs. For immediate and delayed CPM, the mean difference for total costs was $6,528 (SE $2,243) and $16,744 (SE $5,017), respectively. In multivariable analysis, the CPM group had a statistically significant increase of 16.9 % in mean total costs compared with the no-CPM group (p < 0.0001). Human epidermal growth factor receptor 2/neu-positive status, receipt of radiation, and reconstruction were associated with increases in total costs.

conclusionsCPM significantly increases short-term healthcare costs for women with unilateral breast cancer. These patient-level cost results can be used for future studies that evaluate the influence of costs of CPM on decision making.

Indexed as

Health Care CostsBreast NeoplasmsCase-Control StudiesDecision MakingFemaleFollow-Up StudiesHumansMastectomyMiddle AgedNeoplasm GradingPrognosisProspective StudiesRetrospective Studies

Identifiers

PMID24809301
PMCPMC4125517

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.